Project Review
Review Observed Facts And Committee Assumptions
Which project mix best advances BioCity's capability-expansion and manufacturing goals under a limited round budget? Select a row and inspect the three-layer split: observed facts, committee assumptions, and calculated outputs.
How To Use This Page
Use the project drawer on the right as the canonical interpretation layer.
1. Start With Facts
Treat public stage, public funding facts, evidence summary, and source references as the observed layer.
2. Then Review Assumptions
Requested budgets, screening passes, rubric scores, and milestone costs are committee modelling inputs used to run the simulator consistently.
3. Read Outputs Last
Quality, milestone, cost-effectiveness, need, frontier, and scenario allocations are calculated outputs derived from the formula layer.
Portfolio Review Grid
Select a project row to inspect observed facts, committee assumptions, and calculated outputs.
| Project | Hub | Type | Public Stage | Requested | Min Viable | Optimal | Quality | Hybrid Allocation |
|---|---|---|---|---|---|---|---|---|
BioAscent protein production facility RS1 | BioCity Scotland | Real | operational capability expansion | £80,000 | £50,000 | £75,000 | 7.40 | £47,009 |
BDD OralogiK platform / GMP facility RS2 | BioCity Scotland | Real | platform commercialisation + GMP expansion | £75,000 | £45,000 | £70,000 | 7.60 | £45,835 |
CareRoute P4 | BioCity Scotland | Synthetic | pilot-ready | £50,000 | £30,000 | £45,000 | 7.40 | £37,156 |
BioAscent protein production facility
RS1 · BioCity Scotland
Observed Facts
Public stage
operational capability expansion
Evidence summary
Pioneer Group reports that BioAscent opened a state-of-the-art protein production facility in February 2024, later noting GBP 3.5 million facility investment and more than 85 staff.
Public funding fact
£3,500,000
Source references
- Pioneer Group update: BioAscent protein production facility
- Pioneer Group update: BioAscent investment and headcount
Committee Assumptions
Budget assumptions
Requested £80,000
Min viable £50,000
Optimal £75,000
Screening checks
Mandate Pass
Team Pass
Complete Pass
Budget Pass
Milestone Pass
Compliance Pass
Criterion scores
Strategic fit 8/10
Team 8/10
Feasibility 8/10
Market 8/10
Evidence 8/10
Milestone readiness 8/10
Capital efficiency 7/10
Frontier potential 7/10
Risk penalty 4/10
Milestone assumptions
Integrate in-house protein production into customer programmes
Cost £50,000 · Importance 8/10
Readiness 8/10 · Confidence 8/10 · Unlock value 8/10
Calculated Outputs
Quality score
7.40
Milestone score
8.00
Cost-effectiveness
0.160
Need score
25,600
Frontier score
7.65
Hybrid allocation
£47,009
Weight 36.2%